Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria

NCT ID: NCT06522334

Last Updated: 2025-03-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-28

Study Completion Date

2034-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death.

There are no additional interventions regarding this registry.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Lung Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of interstitial lung disease
* written informed consent

Exclusion Criteria

* to not comprehend and rightfully judge participation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ludwig Boltzmann Institute for Lung Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Robab Breyer-Kohansal

Head of Department for Internal Medicine and Pneumology Clinic Hietzing

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Klinik Hietzing

Vienna, , Austria

Site Status RECRUITING

Klinik Penzing

Vienna, , Austria

Site Status RECRUITING

Ludwig Boltzmann Institut for Lung Health

Vienna, , Austria

Site Status RECRUITING

Klinik Ottakring

Vienna, , Austria

Site Status RECRUITING

Klinik Floridsdorf

Vienna, , Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Robab Breyer-Kohansal

Role: primary

+431 80110 2471

Katharina Marth

Role: backup

Marie-Kathrin Breyer

Role: primary

019106042002

Piotr Cichon

Role: backup

+431 91060 42008

Marie-Kathrin Breyer

Role: primary

019106042002

Robab Breyer-Kohansal

Role: backup

+431 80110 2471

Georg-Christian Funk

Role: primary

+431 49150 2201

Sophie Marie Rundel

Role: backup

Arschang Valipour

Role: primary

+431 27700 72208

Mathis Hochrainer

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ILD Registry

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bronchoscopy Registry
NCT02741089 UNKNOWN
Interstitial Lung Disease Exacerbations Study
NCT06685874 ACTIVE_NOT_RECRUITING